63,779 Shares in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Bought by Marquette Asset Management LLC

Marquette Asset Management LLC purchased a new position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLTGet Rating) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 63,779 shares of the company’s stock, valued at approximately $130,000. Marquette Asset Management LLC owned 0.17% of Bolt Biotherapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Northern Trust Corp increased its position in shares of Bolt Biotherapeutics by 4.3% in the 4th quarter. Northern Trust Corp now owns 194,893 shares of the company’s stock worth $955,000 after purchasing an additional 8,113 shares during the last quarter. Woodline Partners LP increased its position in shares of Bolt Biotherapeutics by 2.3% in the 4th quarter. Woodline Partners LP now owns 403,357 shares of the company’s stock worth $1,976,000 after purchasing an additional 9,008 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Bolt Biotherapeutics by 13.0% in the 1st quarter. Bank of New York Mellon Corp now owns 91,293 shares of the company’s stock worth $249,000 after purchasing an additional 10,475 shares during the last quarter. PDT Partners LLC bought a new stake in shares of Bolt Biotherapeutics in the 1st quarter worth about $33,000. Finally, Qube Research & Technologies Ltd increased its position in shares of Bolt Biotherapeutics by 204.2% in the 4th quarter. Qube Research & Technologies Ltd now owns 45,640 shares of the company’s stock worth $224,000 after purchasing an additional 30,638 shares during the last quarter. Hedge funds and other institutional investors own 69.25% of the company’s stock.

Bolt Biotherapeutics Trading Down 1.7 %

Shares of NASDAQ:BOLT traded down $0.03 during trading on Friday, reaching $1.72. 94,084 shares of the company’s stock traded hands, compared to its average volume of 234,240. The company has a debt-to-equity ratio of 0.10, a current ratio of 9.73 and a quick ratio of 9.73. Bolt Biotherapeutics, Inc. has a 12 month low of $1.39 and a 12 month high of $14.18. The company has a 50 day moving average of $2.08 and a 200-day moving average of $2.15.

Wall Street Analysts Forecast Growth

Separately, SVB Leerink downgraded shares of Bolt Biotherapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $8.00 to $4.00 in a research report on Thursday, August 11th.

Insider Activity at Bolt Biotherapeutics

In related news, major shareholder Holdings A/S Novo sold 800,000 shares of the business’s stock in a transaction dated Wednesday, July 13th. The shares were sold at an average price of $2.00, for a total transaction of $1,600,000.00. Following the completion of the sale, the insider now owns 3,703,991 shares of the company’s stock, valued at approximately $7,407,982. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 22.90% of the company’s stock.

Bolt Biotherapeutics Profile

(Get Rating)

Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.

Featured Stories

Institutional Ownership by Quarter for Bolt Biotherapeutics (NASDAQ:BOLT)

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.